Home Sports CVS Health (CVS) Q2 2021 Earnings Call Transcript | The Motley Fool

CVS Health (CVS) Q2 2021 Earnings Call Transcript | The Motley Fool

146
0

CVS Health (NYSE: CVS)
Q2 2021 Earnings Call
Aug 04, 2021, 8:00 a.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Ladies and gentlemen, good morning, and welcome to the CVS Health second-quarter 2021 earnings conference call. [Operator instructions] As a reminder, today’s conference is being recorded. I would now like to turn the call over to Susie Lisa, senior vice president of investor relations for CVS Health. Please go ahead.

Susie Lisa — Senior Vice President of Investor Relations

Thank you, and good morning, everyone. Welcome to the CVS Health second-quarter 2021 earnings call. I’m Susie Lisa, senior vice president of investor relations for CVS Health. I’m very excited to be on the call with you today and to have the opportunity to work with you going forward.

I’m joined this morning by Karen Lynch, president and chief executive officer, and Shawn Guertin, executive vice president, and chief financial officer. Following our prepared remarks, we will host a question-and-answer session that will include Alan Lotvin, president, pharmacy services; Dan Finke, president, healthcare benefits; Neela Montgomery, president, retail and pharmacy; and Jon Roberts, chief operating officer.

Our press release and slide presentation have been posted to our website, along with the Form 10-Q that we filed with the SEC this morning. During this call, we will make certain forward-looking statements reflecting our current views related to our future financial performance, future events, industry, and market conditions, as well as the expected consumer benefits of our products and services and our financial projections.

Our forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from what may be indicated in them. We strongly encourage you to review the information in the reports we file with the SEC regarding these risks and uncertainties, in particular, those that are described in the cautionary statement concerning forward-looking statements and Risk Factors section in our most recent annual report on Form 10-K, this morning’s earnings press release and included in our Form 10-Q.

During this call, we will use non-GAAP financial measures when talking about the company’s performance and financial condition. By SEC regulations, you can find a reconciliation of these non-GAAP measures to the comparable GAAP measures in this morning’s earnings press release and the reconciliation document posted on the Investor Relations portion of our website. Today’s call is being broadcast on our website, where it will be archived for one year. Now it’s my pleasure to turn the call over to Karen.

Karen Lynch — President and Chief Executive Officer

Good morning, everyone, and thank you for joining our call today. This was another strong quarter for CVS Health. We are playing an integral role in connecting experiences across the healthcare system to deliver better health outcomes. This is what truly differentiates us and generates our growth.

In the rapidly changing U.S. healthcare environment, we have proven that we can bring solutions at scale to meet individual health needs however they evolve. Our COVID-19 testing and vaccination campaigns for millions of Americans are just one example. We meet customers where they are.

We are there when and how they want to access care. That is what’s driving growth across our company, and it’s where we’ll continue to focus our innovation and investments. During the second quarter, we delivered revenue growth of 11%. We generated adjusted earnings per share of $2.42 and a strong cash flow from operations of $5.8 billion.

We are raising our adjusted earnings per share guidance from $7.70 to $7.80. This reflects the continued positive momentum across our business with growth both in new and current markets. Today, we announced an essential investment in our employees. We will raise the minimum wage for our colleagues to $15 an hour by July 2022.

This wage increase will boost our competitive edge in a tight retail labor market. We estimate it creates an incremental $600 million in labor costs over three years. Approximately $125 million of that impact will be in the final four months of this year. Increasing our minimum wage for hourly employees will help attract and retain the talent needed for our customer-centric business approach.

Just as critical, it aligns with our values and our purpose and builds on a history of our investment in our people. Our businesses delivered a strong performance, highlighted by overall sales and earnings outperformance and sequential margin improvement. Customers realize the value we are providing across our CVS Health assets, which results in increased customer retention rates and new wins. In healthcare benefits, results were powered by growth in our government business.

Our medical benefit ratio of 84.1% was modestly above expectations, driven by COVID-related costs. Underlying non-COVID costs emerged favorably. We continue to believe aggregate medical costs will modestly exceed baseline levels during the second half of the year. In addition to solid performance in our core business, we are leveraging our broad and unique portfolio of assets with our first CVS-Aetna co-branded offerings.

CVS Health

We have submitted our exchange regulatory filings for a January 2022 entrant in eight states outlined in our supplemental earnings materials. With Aetna’s strong networks and CVS’s significant local presence, we believe we are creating a compelling new offering that combines health insurance, pharmacy, our retail presence, and behavioral health services. This is something that no one else can deliver. The 2022 national account selling season in healthcare benefits has been marked by a somewhat compressed industrywide pipeline.

Employers have been focused on developing strategies for vaccinations and other return to work activities. As a result, we concentrated on client retention, delivering a solid development of 97%. For those cases that were out to bid for 2022, we have successfully secured new business and introduced new differentiated products. For example, our virtual first primary care product is the only nationwide program to offer long-term dedicated virtual primary care and a traditional in-person national network, including MinuteClinics and HealthHUB.

Turning to pharmacy services. We outperformed expectations, delivering 9.8% revenue growth and robust operating income growth. We continue to build momentum in specialty pharmacy, with revenue up 8.9% year over year. Looking ahead, we have maintained an impressive 98% retention rate with more than 80% of renewals complete.

We have also driven solid new business results, winning over $8 billion in recent gross sales next year. We remain well-positioned for continued specialty and pharmacy growth in 2022. The differentiation we offer is significant. It reflects our integrated offering with in-store, mail order, and specialty services.

We added nearly 1 million new integrated pharmacy and medical members through the 2021 and 2022 selling seasons alone. This is a testament to our success in the marketplace from the aligned interest and value we bring to our customers. Our retail segment continues to play a crucial role as part of our community-focused strategy. We are a vital local health destination for millions of Americans who are resuming more normal activities and fueling macro improvements in the economy.

Our second-quarter results for retail outperformed our expectations and the market. In our pharmacies, we grew prescription market share to over 26%. Importantly, our customer-centric programs continue to improve adherence for our patients. At the same time, we saw a solid rebound in front store sales, which increased nearly 13% in the quarter, with strength across all categories.

Nearly two-thirds of that growth was driven by health and wellness products. Similarly, pharmacy script growth in the quarter was strong, up more than 14% year over year, a third of which is attributable to COVID vaccines. We now administered 30 million vaccines and 29 million tests through the inception of the program. Over the past two months, approximately 40% of vaccines we helped were to members of underrepresented communities, a rate at or higher than the benchmark population.

Our effort to make the vaccine accessible and convenient for all Americans continues. However, vaccination rates are slowing from a peak in April despite the impact of new variants. Our COVID work is a powerful example of the trust and relationships with consumers, augmented by our local presence and digital tools. For customers introduced to us through COVID testing, approximately 12% have subsequently chosen to fill new prescriptions or get their COVID vaccine at CVS Health.

This helped drive overall strong script growth in the quarter. The COVID testing outlook remains strong. As public health recommendations evolve, we are prepared and continue to play a critical role in helping Americans prevail against the pandemic. I’m grateful for the continued dedication and tireless efforts of my nearly 300,000 colleagues.

We are making considerable progress across critical drivers of our growth. The first is our role in care delivery. We continue to focus on our integrated platform to expand access to local, affordable, and connected care. HealthHUBs represent one of many channels and lower-cost care sites that allow us to address individual health needs.

Aetna commercial members in the no copay, low copay product are utilizing our MinuteClinics in our health hubs more frequently, more than twice as often as members without these benefits. We expanded the spectrum of health services we offer to include standard services usually done in primary care settings such as chronic care management like diabetes and behavioral health, a critical area of need that will continue beyond the pandemic.

We expanded our care concierge program to support our Medicare members, rolling out the HealthHUB Stars program planned to close gaps in the quality of care. Early intervention results are promising as they demonstrate the substantial reach and a high engagement rate of 67% for various health screenings such as diabetes and cancer.

The second key area is technology. We are using the power of our digital capabilities to reinvent how consumers experience their care by creating choice, expanding access, and reducing complexity. And we are creating new sources of value while accelerating the speed, flexibility, and launch of new health solutions. Today, we regularly serve more than 35 million unique digital customers across our CVS Health assets.

Our digital customers are essential. Digital retail customers spend 2.5 times more in our front store, manage 1.5 times more scripts and remain customers longer than other pharmacy patients. And customers who engage with us digitally have lower medical costs related to personalized data insights that guide health behaviors. This quarter, we also saw more than 37% of specialty prescriptions initiated digitally from the 85% of our pharmacy specialty members who have opted in to our digital program.

Building these trusted digital relationships with customers generates new growth opportunities across all of our businesses. At the same time, we are reengineering our cost structure by simplifying operations to benefit both customers and our own colleagues. Our technology-driven programs leverage blockchain, drive cloud migration and intelligent automation and streamline processes to accelerate results and generate more significant impact. One example is a specialty pharmacy script automation program that uses A.I. to yield better results quickly while eliminating more than 30 manual steps, such as benefit verification and prior authorization.

Our commitment to shareholders, customers, and communities we serve does not stop at commercial product offering. CVS Health plays a vital role in the health and vitality of the communities where we live, work, and serve. Our long-standing commitment to corporate social responsibility focuses on four areas: healthy people, healthy business, healthy communities, and a healthy planet. Together, these efforts create our sustainability road map known as Transform Health 2030.

It represents an ambitious but achievable agenda that aligns with eight of the U.N. sustainable development goals. CVS Health is investing in inclusive wellness, economic development, and advancement opportunities for our colleagues and suppliers. We are also making social impact investments that will improve health outcomes nationwide, making a critical difference in our pandemic work. In addition, we have set science-based targets to reduce our greenhouse gas emissions by 67% by 2030 from a 2014 baseline.

I am proud of what we’ve achieved, but there is much more to do, and I’ll provide regular updates about our continued progress. In closing, CVS Health is the leading health solutions company with a broad and unique set of assets. We are accelerating our pace of improvement to drive value for our customers, communities, people, and shareholders. Our unparalleled capabilities, reach and enduring relationship with the consumer uniquely positions us to support them throughout their lifetime while also providing multiple avenues for sustained growth for our company.

I’ll turn now to Shawn Guertin, who recently joined CVS Health as executive vice president and chief financial officer in late May and has already made an impact. His deep healthcare expertise, financial acumen, and strategic mindset will be instrumental to the successful execution of our strategy. Shawn?

Shawn Guertin — Executive Vice President and Chief Financial Officer

Thank you, Karen, and good morning, everyone. I’m very excited to be at CVS Health, particularly at such a dynamic and critical time, not only for our company but for our healthcare system as a whole. Our differentiated portfolio of capabilities and local community presence creates a compelling competitive advantage that improves healthcare access and outcomes across a broad population while generating strong cash flow and value for all our stakeholders.
I look forward to executing our growth strategy and reshaping the healthcare experience for the people we serve.

I’ll first discuss our second-quarter financial results. As Karen stated, we delivered another quarter of outperformance across each of our businesses, exceeding our expectations and further demonstrating the strength of our collective enterprise. Total revenues of $72.6 billion grew 11% year over year and reflected vital contributions from each segment. We reported an adjusted operating income of $4.9 billion and adjusted earnings per share of $2.42.

We continue to generate excellent cash flow in the second quarter, with year-to-date cash flow from operations now exceeding $8.7 billion. Further, we have repaid $5.4 billion in debt during the first half of the year. All our cash flow metrics exceeded our internal forecast during the quarter. Moving to the segments.

Health care benefits total revenue increased 11% year over year, driven by our continued growth in our government services business, slightly offset by the repeal of the health insurance fee or HIF. Our Medicare franchise continues to perform very well, with quarterly sequential membership growth across all products. Medicare Advantage membership slightly exceeds our prior expectations and is now on track to be up 9% to 10% for the entire year. Dual Special Needs Plans membership grew by double digits sequentially and has more than doubled year over year, reflecting our strategic focus in this business.

Medicare supplement and prescription drug plan membership also increased in the quarter, providing a sustained strong pipeline of opportunities for future conversions to Medicare Advantage. Our midyear Medicare risk-adjusted revenue settlement was in line with our expectations. Finally, for our prescription drug plan business, we are pleased with our bid position below the 2022 low-income benchmark in all our targeted regions. Health care benefits adjusted operating income exceeded our projections for the quarter but was down materially on a year-over-year basis due to the depressed levels of utilization observed in the second quarter of 2020 at the start of the pandemic.

The medical benefit ratio for the quarter of 84.1% was slightly higher than our forecast, driven by higher-than-expected COVID-related costs, which, while materially lower than the first quarter, did not fall off as much as we had forecast. Underlying non-COVID utilization continued its return toward normal baseline levels and was slightly favorable versus our expectations.

The combined result was an MBR slightly higher than our forecast for the quarter. We remain comfortable with the adequacy of our reserves, recording a modest amount of favorable prior year development in the quarter while days claims payable of 48 is consistent with both the first quarter of this year and the fourth quarter of 2020.

Turning to pharmacy services. We continue to deliver exceptional value for our customers by producing industry-leading low single-digit drug trends. This value proposition allowed us to build strong revenue growth of nearly 10% versus last year, primarily driven by network volume and specialty pharmacy growth. Total pharmacy claims process increased by more than 11% versus last year, with approximately half attributable to net new business wins from our 2021 selling season and another quarter due to COVID vaccine administration.

Our specialty network and maintenance choice business lines all delivered sequential claims growth in the quarter. Pharmacy services adjusted operating income exceeded expectations in the second quarter, up more than $400 million or 32% year over year. The three primary drivers of this increase are improved purchasing economics, reflecting the products and services of our group purchasing organization launched in the second quarter of 2020, specialty pharmacy, including our 340B claims administration business, and increased pharmacy claim volumes. These favorable items were partially tempered by ongoing client pricing pressure.

Lastly, it’s important to note that the initiation of our group purchasing organization and specific generic specialty launches in the second quarter and second half of 2020, respectively, created relatively low comparisons in the first half of 2021 that will increase significantly in the second half of the year. Therefore, we expect a much smaller incremental year-over-year improvement in operating income in the second half of this year. Retail also delivered strong results this quarter, exceeding expectations. Total revenue of nearly $25 billion increased by $3 billion or 14% year over year.

This improvement is driven by three main components: one, approximately a third or $1 billion is attributable to the nearly 17 million COVID vaccines and more than 6 million COVID tests administered during the second quarter; two, an additional one-third or another $1 billion is due to the broad quarantine restrictions, and civil unrest experienced last year that depressed results in the second quarter of 2020; three, the final third or remaining $1 billion was driven by a combination of improved pharmacy growth and mix during the second quarter as well as broad strength in front store trends. Front store revenue increased by nearly 13%, while pharmacy prescription volume was up 14%, including COVID vaccines.

This strong revenue growth, combined with a 340-basis-point improvement in adjusted operating margin, produced adjusted operating income well ahead of our forecast and an increase of nearly $1 billion years over year. COVID testing and vaccines, immaterial in Q2 2020, represent approximately half of the operating income increase.

Second-quarter 2021 results also reflect a legal settlement related to an antitrust matter worth $125 million, which is included in our GAAP and non-GAAP results. Turning to cash flows and the balance sheet. Cash from operations remained strong at $5.8 billion for the quarter and $8.7 billion year-to-date. We paid down $2.4 billion of long-term debt in the quarter while returning $650 million to shareholders through dividends.

Since the close of the Aetna transaction, we have paid down a net $17.6 billion in long-term debt. Our commitment and discipline in this area were recognized during the quarter as S&P raised our credit outlook from stable to positive. Let me now turn to our updated guidance for 2021 and share some preliminary thoughts regarding 2022. But first, I want to provide a framework of the pandemic-related dynamics that will impact our business over the remainder of the year in the interplay between the retail and healthcare benefits segments.

As mentioned, our retail segment benefited from COVID solid testing and vaccine administration services in the second quarter but began to see vaccines fall below expectations in May and June. As a result, we have reduced our forecast for vaccine earnings to below the midpoint of our original range for the entire year. Given the current environment’s ongoing fluidity in healthcare benefits, we have incorporated a higher estimate of COVID-related costs in the second half of the year. As a result, our full-year MBR is approximately 20 to 30 basis points higher than our previous forecast while still well within our range.

Overall, we believe the combined impact of a reduced outlook for vaccines in retail and a slightly higher MBR and healthcare benefits now make the pandemic modestly negative for 2021. Despite this, given our strong performance in the quarter and solid outlook, we are increasing our guidance. We are raising full-year 2021 total revenue guidance to a range of $280.7 billion to $285.2 billion, representing year-over-year adjusted revenue growth of 4.5% to 6.25%. We are also raising adjusted EPS guidance from $7.70 to $7.80 per share.

The significant earnings outperformance in the second quarter is reflected in our updated full-year guidance but is partially offset by three fundamental headwinds during the second half of 2021. The first is expectations for full-year COVID-19 vaccine volumes to be below the midpoint of our original guidance. As I mentioned earlier, we saw vaccinations peak in April, then decline in May and June. Although the recent rise in COVID-19 cases has caused a reacceleration in the first dose trend, we believe it to be prudent to adjust our full-year outlook for vaccines to a range of 32 million to 36 million.

This includes a limited contribution from the administration of pediatric vaccines but does not assume any assistance from booster shots. Overall, despite the slowdown in vaccine administration, we continue to be pleased with our expanded and strengthened customer relationships stemming from our local presence and see ongoing customer connectivity from the significant role we play in combating the pandemic in our local communities. The second item is the investment in wages that Karen highlighted. Our work to retain and attract talent includes an additional $600 million investment in wages over three years, primarily for our retail colleagues and pharmacy technicians, with approximately $125 million impacting the last three months of 2021.

Finally, the third item is increased investments in the second half of 2021, reflecting our efforts to drive and support growth, enhance our consumer experience and improve our cost structure in 2022 and beyond. In aggregate, these 3 items are expected to negatively impact second-half adjusted EPS by approximately $0.25 per share. In addition to increasing our EPS guidance, we are also raising our expectations for cash flow from operations by $500 million to a range of $12.5 billion to $13 billion. Our expectations for gross capital expenditures range from $2.7 billion to $3 billion to fund organic growth initiatives and our expanded investments in technology and digital.

We remain committed to ongoing deleveraging and our investment-grade rating target. By segment, we are maintaining our full-year adjusted operating income guidance of $5.25 billion to $5.35 billion for healthcare benefits. As discussed, our outlook assumes a slightly higher full-year MBR by 20 to 30 basis points to reflect the higher COVID costs observed in the second quarter and our expectation that slightly higher COVID costs will continue into the second half. Our forecast assumes that non-COVID utilization will return to normal baseline levels by the fourth quarter.

This MBR pressure is largely being offset by an improved revenue outlook and operating expense management. It’s also worth recalling the natural seasonality of the healthcare benefits segment, with fourth-quarter operating income typically the lowest of the year. We believe that our forecast is appropriately positioned, given that there remains a high degree of uncertainty in terms of how COVID will play out during the second half of the year. For pharmacy services, given the strength in the quarter and visibility to the remainder of the year, we are increasing our full-year 2021 adjusted operating income guidance to $6.45 billion to $6.55 billion, representing year-over-year growth of 13.5% to 15.25%.

While we expect the factors driving second-quarter performance to continue to benefit the second half of 2021 due to the timing elements I discussed earlier, we do not anticipate the same level of year-over-year growth observed in the first half of 2021. We are maintaining our full-year 2021 segment guidance for adjusted operating income in the range of $6.6 billion to $6.7 billion for retail.

Given the dynamic environment relative to the pandemic and its impact on vaccines, testing, and front store sales, we have taken what we believe to be a prudent posture in our outlook. We have not fully pulled through the favorability we observed in the second quarter to the entire year. This full-year guidance also reflects the reduced view for vaccines and the impact of the wage investment, approximately 80% of which is experienced in the retail segment.

You will find further details in the slide presentation we posted to our website this morning. Moving on to 2022. While it is premature to provide forward-year guidance, I want to share some preliminary thinking on some of the more visible puts and takes we are considering for 2022. Starting with tailwinds.

It is reasonable to expect benefits from one, strong selling seasons in the pharmacy services segment and in national commercial accounts in the healthcare benefits segment; two, anticipated lower COVID-related costs and improved Medicare risk-adjusted revenue reimbursement in the healthcare benefits business; and three, continued contributions from our ongoing cost savings initiatives.

For headwinds, we anticipate: first, consistent pressure in Pharmacy Services from client price improvements and reimbursement pressure in retail, both of which are constant industry headwinds, which we seek to mitigate through improved purchasing economics; second, the impact of annualizing the increase to minimum wage across the company; and third, uncertainty regarding the expected revenue from COVID vaccines and testing in our retail operations.

Lastly, I’d remind you that our standard practice is not to include any estimates of prior year development or realized capital gains in our forward-looking guidance. On a year-to-date basis, these two items comprise approximately $0.15 per share.

Again, this is not a comprehensive outlook for 2022 but represents some of the critical items likely to influence performance next year. To conclude, CVS Health continues to produce strong results as we execute our differentiated strategy putting the consumer at the center of what we do and redefining the integrated delivery of healthcare. I look forward to updating longer-term financial targets at our Investor Day event this December in detailing our key priorities, positioning CVS Health to deliver sustainable, long-term profitable growth, and returning to a more balanced and strategic program of capital deployment. We will now open the call to your questions.

Operator?

Questions & Answers:

Operator

[Operator instructions] We’ll take our first question from Lisa Gill with J.P. Morgan. Please go ahead.

Lisa Gill — J.P. Morgan — Analyst

Thanks very much, and thank you for all the detail. Shawn, just going back to your thoughts around 2022, am I thinking about this correctly? If I take the midpoint of this year at $7.75, add back the $0.25 that you talked about, we get to $8 minus the $0.15 as we think about the fee, and capital gains get us to $7.85. And then, how do I feel about the headwinds and tailwinds that you talked about? Are they reasonably equal between them? Is there any other color you can give us as we think about the puts and takes going into next year?

Shawn Guertin — Executive Vice President and Chief Financial Officer

Yes. I think I’d be careful on the specific math there because to some extent, as I mentioned, for example, about vaccines and testing revenue, there’s just uncertainty about the level of those things. And I’d also not add back the total $0.25 as an example because of the minimum wage impact, which is only for four months. And obviously, that will annualize next year.

So there’s some moving pieces sort of in there. But honestly, some of these things, I think we can see, are going to be factors, but we don’t have quantified them entirely at this point. But I do believe when we talk about 2022 if it’s worth talking about a couple of things. At the outset, we remain very well-positioned in our core businesses, and our operating performance is solid, as evidenced by the last couple of quarters of results.

And as I mentioned in my remarks, I don’t want to provide 2022 guidance today, but I recognize that there are previous targets out there for a low double-digit earnings growth for 2022. And what I would say is, make no mistake, double-digit adjusted EPS growth remains the benchmark that we’re always trying to achieve and, frankly, the model that we’re using in considering the strategic choices we’ll make. But an awful lot had changed since 2019 when that target was out there and stated. And it’s not just the composition of our earnings, but sort of to the point of your question, Lisa, what’s the visibility that we have into how those components will trend forward.

Again, the vaccines and testing and COVID treatment costs are just two good examples of factors, but the direction and the degree are a bit hard to see. So much of this will come down to thinking about what baseline we measure from and how we see these factors playing out here. But as I sit here today, if I consider a starting point of $7.70 to $7.80, I would say at this point, no, that from this forecast baseline, I wouldn’t reiterate the double-digit sort of growth target for 2022. But again, as I mentioned, this says more about the shifting factors.

It does not have anything really to do with the core performance of our business, which has been really outstanding. Obviously, we hope to talk in much more detail about 2022 at our Investor Day and some of the longer-term financial targets and the earnings power of the business.

Lisa Gill — J.P. Morgan — Analyst

And, Shawn, just as my follow-up, I just want to understand, you talked about COVID costs returning as we go into the back half of the year. Can you speak at all of what you’ve seen in the last few weeks with the Delta variant and the potential increase in cost on the COVID side? And then are you seeing any non-COVID price coming down that the people are pushing off elective surgeries because of COVID? Any incremental color would be helpful there.

Shawn Guertin — Executive Vice President and Chief Financial Officer

Yes. So what I would say is in the HCB business. Obviously, there’s a lag in a sort of what we see and any real-time. So we don’t have great insight necessarily into July. But I would say, there certainly has been — I’ve seen several media reports about various facilities beginning to cancel elective procedures again.

And so it does feel like there’s undoubtedly some push in the system on the deferred utilization side again, but again, premature to conclude for HCB. I would say, though, that what we see on the retail side is pretty strong momentum continuing in testing, in particular. And again, while vaccines are still down in July versus the prior month, they’ve probably had a bit of an uptick, as I mentioned in my remarks. So I think. Clearly, you could reasonably infer that there’s sort of the ongoing kind of COVID treatment costs are persisting, certainly into early July here. And again, thus, why we thought it made sense to be a bit more cautious in our MBR outlook for HCB.

Lisa Gill — J.P. Morgan — Analyst

Great. Thank you.

Operator

And we’ll take our next question from A.J. Rice with Credit Suisse. Please go ahead. Your line is open.

A.J. Rice — Credit Suisse — Analyst

Hi, everybody. Welcome, Shawn and Susie. Anyway, I appreciate the conversation in the last couple of conference calls about how the three businesses can work together. When you look at it today, what are the leading opportunities for the businesses to the retail pharmacy services and the benefits business to capitalize on that are still in front of the company? Can you highlight a couple of things that you are mainly focused on and see as opportunities?

Karen Lynch — President and Chief Executive Officer

Yes. I would highlight a couple of things in front of us. One is, as you know, we have more opportunities to expand our digital access and digital connections. We’ve seen across the board, with our following best actions using digital links we’ve seen for those individuals, we’ve seen reductions in overall medical costs.

We also have the opportunity to expand our home service and delivery. As you know, we are in Corum today. We have kidney care, but I do think that there are more expansive opportunities. It’s a $100 billion-plus market that I think we have more opportunities to penetrate and enhance our overall care delivery.

So I would point to those two as ones. And then I think there’s more that we can do with just the fundamental core business through integration through selling more of our products, capturing more share of wallet, driving benefit designs across to support lower sites of care like MinuteClinic and the HealthHUB. So those would be a few I would comment on. Thanks for the question, A.J.

A.J. Rice — Credit Suisse — Analyst

Yes. Maybe just a quick follow-up. I know the slide deck says that the priority remains to continue to pay down debt. With Shawn as CFO on board, what point do you think you might look at tuck-in acquisitions a little more actively? Share repurchase, any of those types of things? What’s the time frame for that?

Shawn Guertin — Executive Vice President and Chief Financial Officer

Thanks, A.J. So if I thought about the near term being sort of the rest of this year, but primarily 2022, we have $4 billion of debt or thereabouts, a little more than that maturing, and it would be our intention to continue to deliver by paying that off. However, if you think about the level of our cash flows in ’21, if we achieved a similar status of cash flow next year, even with the dividend, that would still leave a lot of room for other capital deployments, potentially M&A, potentially dividend increase and potentially share repurchase. So I think 2022 is a year where we begin to do that in a potentially more limited way but still meaningful.

What I would say is long-term; as I think about this, and as you’ve heard me say before, my first use of that and my most preferred use of that capital all the time is to grow the business. And undoubtedly, that there are capabilities that we will need over the next few years to sort of affect our strategy as efficiently as possible. And so, M&A is a part of that. But I’ve also found that balanced capital deployment tends to produce the best long-term results.

And so that is a combination of M&A, a dividend that moves up as EPS moves up, and share repurchase that’s accretive to your EPS growth on sort of a steady basis.

Susie Lisa — Senior Vice President of Investor Relations

Next question, please?

A.J. Rice — Credit Suisse — Analyst

Thanks a lot.

Operator

We’ll take our next question from Ricky Goldwasser with Morgan Stanley. Please go ahead. Your line is open.

Ricky Goldwasser — Morgan Stanley — Analyst

Yes. Hi. Good morning. Thank you for all the detail, and congrats on an excellent quarter.

So my main question, Karen, is around sort of the relationship and how you think about your Medicare Advantage book of business and your vision for how you’re going to evolve the HealthHUB presence. I think you talked about the care concierge for Medicare. Just curious to see how that kind of like marketplace is really kind of like shaping your thing of what health hubs would look at the future versus what it is today? And then the follow-up question would be to Shawn. So, Shawn, when you talked about second-half guidance, you mentioned investments in future growth are a headwind.

You didn’t mention it as a headwind for fiscal-year 2022. So, from a modeling perspective, should we think about these investments just as happening in the second half? Or should we also run rate them as we adjust our models for next year?

Karen Lynch — President and Chief Executive Officer

Ricky, let me just start with relative to Medicare. First of all, that is one of our single most significant growth opportunities, continuing to sell more Medicare, driving the duals. And so, we do think that is an ample opportunity for growth on an ongoing basis. As we think about care delivery and Star’s performance, the health hubs will play a critical role.

But as I said, we have to have a broad, expansive approach to care delivery, particularly as it relates to Medicare patients. So the health hub will play a role. As you know, we have the $0 copay, low copay now asking — demonstrating that we can have follow-up visits at our health hubs, but we need to expand our capabilities in the home, and we need to make sure that we’re staying digitally connected to them. But this new program that we had just recently introduced as part of our planned rollout in the HealthHUB is really intended to close gaps in care.

And the more that we close gaps in care, the better Stars performance we get, the better revenue we get. So you can see that cycle. And that really is an ample opportunity for us. But I really want you to think about Medicare care delivery and a broader role with health hubs being part of that care delivery strategy.

Shawn, let me turn it over to you.

Shawn Guertin — Executive Vice President and Chief Financial Officer

Yes. In terms of the second half guidance, Ricky, I think there are some investment levels here, and one of them each year is when we do have growth better than our original plan, for example, as we foresee in PSS now. We have to sort of staff up and be prepared for that higher growth, so that’s always an element. So part of your question is how you feel about, in essence, the ’23 development that we’ll achieve in 2022.

And I think broadly, there’s — I would not run rate the whole thing, but I do think there are pieces that tend to run pace forward in the business, whether they’re ongoing investments we make in Medicare distribution. And as I mentioned, in staffing up for customers. So as I sit here today, I wouldn’t run rate the whole thing. A lot of this is still to be determined, but they’re probably a piece that continues if we continue on the trajectory that we’re on.

The other element I would say about second-half guidance with some of this is some of the spendings gets sort of pushed back into the year, more toward the end. I think you some kind of take that with the natural seasonality of the healthcare benefits business, and that would tend to get sort of a slope of earnings for the rest of the year where Q4 is likely less than Q3.

Ricky Goldwasser — Morgan Stanley — Analyst

Thank you.

Susie Lisa — Senior Vice President of Investor Relations

Next question?

Operator

We’ll take our next question from Ralph Giacobbe with Citigroup. Please go ahead. Your line is open.

Ralph Giacobbe — Citi — Analyst

Great. Thanks. Good morning. Maybe just on the labor commentary.

First, are you seeing underlying wage pressure outside of the minimum wage lift? And then just wanted to clarify the numbers because I think you said the cost to be $600 million, $125 million the last four months of this year. But I think you also said it would stretch over three years. So I just wanted to reconcile that versus that July 22 — sorry, July 2022 date that you put out there.

Karen Lynch — President and Chief Executive Officer

Ralph, let me just start with the minimum wage adjustment. It’s a series of investments that we’ve been making for our employees since the pandemic, and we are seeing 65% of our employees that are already at or above $15 an hour. This is a very targeted investment for our pharmacy technicians, our front store colleagues, and we will start a series of wage increases beginning in September, which is really what’s driving that $125 million impact to the latter half of the year. Obviously, it’s a tight labor market.

We are paying attention. We’ve got a lot of hiring to do to support growth. And so far, we see pressure, but we’ve been managing through it. But we’re watching that labor market that we see impacts in the stores, and that’s part of why we’re making this wage investment today.

Shawn, do you want to answer the three-year question?

Shawn Guertin — Executive Vice President and Chief Financial Officer

Yes. Ralph, the way this will play out over the next few years is, as you mentioned, there would be — the change in September would be $125 million for the last four months of this year. That will annualize next year, but there’ll also be a second change sort of in July of next year, I believe. So the total cost of this in 2022 will be $485 million, which is a step up, if you will, to about $360 million from the $125 million.

That second step in July ’22 will annualize again in ’23, but not to the same degree. So the total cost is right around $600 million by the time you get to ’23, and that’s a step-up year over year from ’22 million to ’23 million of about $115 million.

Ralph Giacobbe — Citi — Analyst

Got it. All right. That’s helpful. And then just a quick follow-up.

I just want to clarify, Shawn. I think you said you would not factor in low double-digit growth on a 7.75 basis. I think I heard that. But if I do look at consensus, it factors about 7% growth.

So we’re not at that double-digit level. And given your commentary around capital deployment alone, are you willing to say if there is comfort in that sort of mid-single-digit EPS? Or is it just still too early to even give that comfort or clarity? Thanks.

Shawn Guertin — Executive Vice President and Chief Financial Officer

I would say it’s too early for me to give you specific guidance. But if you go back to what I said, I think the businesses are performing very well, and we will have the ability potentially to deploy some capital next year. So I certainly wouldn’t dismiss that as something that does not sort of in the thinking or not a viable target. But again, I want to stay away from giving precise guidance, but the core fundamentals of our business are excellent right now.

And again, with the return to more balanced capital deployment, I certainly feel good about sort of the longer-term trajectory.

Ralph Giacobbe — Citi — Analyst

OK. Fair enough. Thank you.

Operator

And we’ll take our next question from Mike Cherny with Bank of America. Please go ahead. Your line is open.

Mike Cherny — Bank of America Merrill Lynch — Analyst

Good morning, everyone. Thanks for all the color so far. So I’m going to dance around the ’22 outlook a bit without obviously trying to hold you to anything, Shawn. But as you talked about some of the tailwinds, particularly the strong PBM and commercial selling season so far, can you give us any characteristics of the type of customers you’re winning? What are the actual picks they’re looking at relative to how you’re going to market and what that driving force is? Obviously, you had the federal employee plan specialty that came back that we know about in the pharmacy services.

But beyond that, any characteristics that you can point to that are really resonating in the strong performance year to date?

Karen Lynch — President and Chief Executive Officer

Michael, it’s Karen. As I mentioned in my opening remarks, I very much have a strong one-one. Part of it is due to the integration and the products and services that we’re offering. Part of it is just due to the service delivery that we’ve been delivering to our customers and the value that we’ve been providing to our customers. I will ask Alan and Dan to talk about precisely what they’re seeing and the types of customers that we’re winning in the market.

So, Alan?

Alan Levin — President, Pharmacy Services

Yes. Thank you, Karen. So when you look at the Caremark selling season and the Caremark kind of array of clients, it is a, I would say, relatively normal distribution of clients. We won, obviously, the federal employee program specialty, but we won in the health plan segment.

We’ve won in the employer segment, and we’re winning in the coalition segment. So across the board, we continue to win. And I think the key drivers there are: one, delivering on what is most important to our clients, which is controlling their drug trend; number two, providing kind of an outstanding level of service, so avoiding all — not just avoiding service issues, but proactively addressing our client’s needs; and the third sort of related to the first is innovating, particularly around new programs in a specialty like our oncology program, medical benefits management program. So it’s really — there isn’t a specific segment that’s overperforming other than specialty, obviously, because of the FEP one.

Dan Finke — President, Health Care Benefits

Yes. And I would just add that similar to Alan, we have quite a few areas of focus that are resonating in the market that’s leading to that improved persistency that Karen stated, but also some solid wins in the market. Alan and I have been working closely to improve the further penetration of our integrated offering, specifically in pharmacy, which is resonating really strongly, as well as dental and behavioral health. And then, like Alan, with our innovative solutions, we’re targeting some new capabilities for chronic disease that use the breadth of the assets of CVS like transform diabetes and transform oncology, which is resonating as well as our new access point products like our virtual primary care.

And so that’s really what’s leading to a solid and improved national account selling season.

Mike Cherny — Bank of America Merrill Lynch — Analyst

Got it. If I can, just ask one more. You’ve highlighted a lot of the investments you made in the store base prepared for the COVID vaccines and COVID testing. As you think about your outlook going forward and the uncertainty around what the pacing will be of vaccines, pediatric boosters, etc., what happens to a lot of those costs, the incremental labor, the total staffing that you’ve done in terms of how that should factor into the model on a go-forward basis?

Shawn Guertin — Executive Vice President and Chief Financial Officer

Michael, so you’re right. I mean, we did have to stand up a fairly sizable operation to sort of handle volume like this. And it’s a delicate balance of adjusting that as you see books change, but we sort of see how quickly books can go up and down. So I think we’ve been a bit cautious with that and tried to make sure that we have the capacity if things go in a different direction.

This is an important role that we play, even more, critical now without as many large-scale sites. And so we want to make sure we have the capacity. So as you think — the thing I think that kind of comes off of that is, as you think now about sort of vaccine volume up and down, the marginal impact, right, of those vaccines is probably more significant than average. So it is something that we’re paying very close attention to, but a balance.

Neela Montgomery — President, Retail and Pharmacy

It’s Neela. I’ll just add to that on Shawn’s comments: we started the vaccine campaign with several dedicated clinics, which had dedicated labor. And since then, we’ve expanded to all stores and are seeing about 40% of the appointments as walk-in appointments. So they are really within our existing labor model within the pharmacy.

So that does help us to flex up and down much more with the demand that we see every week.

Susie Lisa — Senior Vice President of Investor Relations

Next question?

Operator

We’ll take our next question from Kevin Caliendo with UBS. Please go ahead. Your line is now open.

Kevin Caliendo — UBS — Analyst

Hi. Thanks. I just want to go through the headwinds and tailwinds and try to figure out — I think we’re all trying to figure out sort of what is the baseline. I know Lisa tried earlier.

When we think about the vax benefit, right, I mean, you sized it earlier, it was $500 million. Was that for the quarter? And how should we think about that benefit for the entire year net-net? And I guess the question really is how to think about what that headwind could be for next year? Like what can we anticipate? Are the economics of the vaccine changing in your opinion? That’s the first one.

And then the second one is, do you think you can still get the same purchasing synergies that you’re seeing this year, next year in the PBM? It sounds like you’re getting massive new growth there. I’m just wondering if you can continue to see the year-over-year kind of growth, which I’m guessing is driven by the purchasing synergies next year.

Shawn Guertin — Executive Vice President and Chief Financial Officer

Yes. I can let Alan comment more deeply on the second one. But what I would say is recall that some of these initiatives, as I mentioned in my comments, were launched sort of midway or in the second half of last year. So the effect we’re seeing year over year is probably is more pronounced than sort of the first half of the year than we’ll see in the second half of the year.

But Alan can comment on the longer-term potential. On the vaccine and the testing economics, as we mentioned, $1 billion of the revenue increase is attributable to those two things in our full-year outlook. The full-year revenue is probably double that. The margin dynamics are probably a little high just this quarter because of some of the timing issues.

But to date, I don’t have any insight into changing reimbursement or the kind of labor model we’re using to sort of deliver those. So I think that’s a reasonable sort of the baseline to begin to work off of as we can — as we think about next year. And again, I mean, as you think about the dynamics here, as you have FDA approval mandates, booster shot, there’s a lot of things. And listen, you could make a bull case if you wanted to on this, indeed, with what’s going on now.

And I wouldn’t dispute that, and I’d acknowledge that if our guide has some upside, this could be a place depending on how things play out. The only kind of caution I would put there is to think about some of the interplays of just looking at this in isolation. So even in sort of inside retail, if we do see an uptick and it does see increased activity, well, what does this mean for cough, cold, and flu for this? What does it mean for the front of the store? And then, obviously, the HCB ripple. So again, I’d acknowledge that there is a bull case that you could make here, but I’d also say this has changed rapidly over the last couple of months.

And I’d just ask you to sort of think about it in a broader context.

Alan Levin — President, Pharmacy Services

And, Kevin, it’s Alan. So when I think about the drivers of purchasing economics on the manufacturer side and the sustainability, the first thing I’d acknowledge is, as Shawn has said, when you launch something new, there’s always going to be an outsized step-up. Having said that, I think the future viewpoint on the ability to create more competition through whether it’s biosimilars and biosimilar to changeability as we saw recently through generics, particularly in the specialty area, we see that as we’re at the beginning of the specialty — the generic era, biosimilar era specialty. So I think that’s sustainable and a good opportunity longer term.

I think the growth of our value creation will grow as volume grows. So as we continue to win new business, we’ll continue to grow there. And the last is we built this platform as a platform for a series of services. So we’ve just launched our first set of services.

We think there are several other ones that we can continue to launch into the market within the GPO that will create meaningful value for both our customers and us.

Susie Lisa — Senior Vice President of Investor Relations

Great. With that, it brings us to 9:00. We appreciate your interest and time. And, Ashley, if you could please give the replay information.

Thank you, all.

Operator

[Operator signoff]

Duration: 28 minutes

Call participants:

Susie Lisa — Senior Vice President of Investor Relations

Karen Lynch — President and Chief Executive Officer

Shawn Guertin — Executive Vice President and Chief Financial Officer

Lisa Gill — J.P. Morgan — Analyst

A.J. Rice — Credit Suisse — Analyst

Ricky Goldwasser — Morgan Stanley — Analyst

Ralph Giacobbe — Citi — Analyst

Mike Cherny — Bank of America Merrill Lynch — Analyst

Alan Levin — President, Pharmacy Services

Dan Finke — President, Health Care Benefits

Neela Montgomery — President, Retail and Pharmacy

Kevin Caliendo — UBS — Analyst

More CVS analysis

All earnings call transcripts

This article represents the writer’s opinion, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become more intelligent, happier, and more prosperous.